We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
McKesson (MCK - Free Report) closed at $321.25 in the latest trading session, marking a -0.09% move from the prior day. This move lagged the S&P 500's daily gain of 1.5%. At the same time, the Dow added 1.12%, and the tech-heavy Nasdaq gained 0.32%.
Coming into today, shares of the prescription drug distributor had gained 2.07% in the past month. In that same time, the Medical sector lost 0.3%, while the S&P 500 lost 6.54%.
Wall Street will be looking for positivity from McKesson as it approaches its next earnings report date. This is expected to be August 3, 2022. The company is expected to report EPS of $5.29, down 4.86% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $63.87 billion, up 1.91% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $23.25 per share and revenue of $264.78 billion. These results would represent year-over-year changes of -1.86% and +0.31%, respectively.
Investors might also notice recent changes to analyst estimates for McKesson. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. McKesson is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that McKesson has a Forward P/E ratio of 13.83 right now. For comparison, its industry has an average Forward P/E of 21.39, which means McKesson is trading at a discount to the group.
Meanwhile, MCK's PEG ratio is currently 1.47. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Dental Supplies industry currently had an average PEG ratio of 2.15 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 174, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MCK in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Stock Sinks As Market Gains: What You Should Know
McKesson (MCK - Free Report) closed at $321.25 in the latest trading session, marking a -0.09% move from the prior day. This move lagged the S&P 500's daily gain of 1.5%. At the same time, the Dow added 1.12%, and the tech-heavy Nasdaq gained 0.32%.
Coming into today, shares of the prescription drug distributor had gained 2.07% in the past month. In that same time, the Medical sector lost 0.3%, while the S&P 500 lost 6.54%.
Wall Street will be looking for positivity from McKesson as it approaches its next earnings report date. This is expected to be August 3, 2022. The company is expected to report EPS of $5.29, down 4.86% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $63.87 billion, up 1.91% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $23.25 per share and revenue of $264.78 billion. These results would represent year-over-year changes of -1.86% and +0.31%, respectively.
Investors might also notice recent changes to analyst estimates for McKesson. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. McKesson is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that McKesson has a Forward P/E ratio of 13.83 right now. For comparison, its industry has an average Forward P/E of 21.39, which means McKesson is trading at a discount to the group.
Meanwhile, MCK's PEG ratio is currently 1.47. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Dental Supplies industry currently had an average PEG ratio of 2.15 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 174, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MCK in the coming trading sessions, be sure to utilize Zacks.com.